We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...